“One of the deep secrets of life is that all that is really worth doing is what we do for others.” – Lewis Carol
Headquartered in North Chicago, USA, AbbVie Inc. is a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe. The company is committed to patient-centered innovation by drawing on its deep expertise in some of the most difficult-to-treat diseases and on its understanding of the patient journey to identify opportunities to create better outcomes at every stage. The patient-centered approach to discovery and development ensures that company remains focused on the goal of improving lives. Research and innovation are the cornerstones of AbbVie’s business as a global biopharmaceutical company. It focuses on developing medicines that deliver strong clinical performance, provide more patient benefit and deliver economic value, particularly where there is significant need around the world in certain disease areas.
AbbVie began as the pharmaceutical leader, Abbott Laboratories, which was founded in 1888. Since then Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products to people in more than 150 countries. It was split from Abbott in 2013 in to a separate entity which would operate as a research-based biopharmaceutical manufacturer. The company employs approximately 28,000 people and markets medicines in more than 170 countries.
The company’s discovery and development efforts are focused on a core set of therapeutic areas where it has proven expertise and where it believes it can have an even greater impact on the disease and how it is managed. These core areas of focus include immunology, kidney disease, liver disease, neuroscience, oncology and women’s health.
As leading experts in autoimmune diseases and therapies, AbbVie is focused on developing new medicines to address chronic progressive diseases in the field of immunology, including rheumatology and dermatology. AbbVie is investigating several diseases which have few or no treatments, including uveitis, hidradenitis suppurativa, pediatric Crohn’s disease, osteoarthritis and lupus.
The company is researching potential therapies for CKD resulting from diabetes and for acute kidney injury in association with major surgeries.
AbbVie’s antiviral program focuses on the development of treatments for chronic hepatitis C virus (HCV), a liver disease that affects more than 160 million people worldwide, with approximately three to four million new cases of infection every year. HCV infections potentially lead to long-term complications and chronic liver disease.
The current innovative research focuses on compounds that have the potential to treat a variety of chronic disabling neurological conditions. The company has several compounds in the early and advanced investigational phases for diseases such as cognitive impairment associated with schizophrenia, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS) — all of which affect millions of people worldwide.
AbbVie’s oncology pipeline includes multiple new molecules in clinical trials being studied in more than 15 cancers and tumor types, including some of the most widespread and difficult-to-treat, such as multiple myeloma and chronic lymphocytic leukemia.
The company is currently investigating a treatment for symptoms related to endometriosis and uterine fibroids. Each affects more than 16 million women throughout the world. Both conditions are highly prevalent and are associated with a number of symptoms including pain, bleeding and infertility.
AbbVie has a diverse product portfolio including several market leading medicines. Some of them are listed below:
Awards & Recognitions
The Road Ahead
AbbVie takes a broad perspective on improving healthcare and are committed to new thinking and approaches. It strives to find new solutions that will enable healthcare systems to bring medical innovation to more patients cost effectively.
Knowing the Key Executives
Richard A Gonzalez, Chairman of the Board and CEO – Prior to AbbVie’s separation from Abbott, Mr. Gonzalez was a 30-year Abbott veteran. He served as Executive Vice President, Pharmaceutical Products Group, where he led the global pharmaceutical business, including commercial operations, research and development and manufacturing. He also served as President and Chief Operating Officer, prior to a brief retirement.
Laura J Schumacher, Executive Vice President, Business Development, External Affairs and General Counsel – She is responsible for AbbVie’s Legal, Licensing and Acquisitions, Government Affairs, Health Economics Outcomes Research, Investor Relations and Public Affairs functions. Prior to AbbVie’s separation from Abbott, Ms. Schumacher served as Executive Vice President, General Counsel and Secretary and had additional responsibilities for Licensing and Acquisitions, as well as the Office of Ethics and Compliance. She serves on the board of General Dynamics.
Benchmark Electronics will develop Qualcomm’s biometric patches to monitor vital signs and track patients